Inquiries Concerning News
Corporate Communications Div.,
The Mitsubishi Chemical Group
TEL: +81-3-6748-7140

News Releases
Archives
Downloads
News Releases
News Releases 2001
October 19, 2001
Mitsubishi Chemical Safety Institute Ties up with Parexel
— Establishes Complete Structure for Conducting Pre-clinical Tests, Clinical Tests and Application of New Drugs
Mitsubishi Chemical Safety Institute Ltd.
Mitsubishi Chemical Safety Institute Ltd. (Head Office: Minato-ku, Tokyo; President: Jiro Saito) has concluded an agreement with Parexel International Corporation (Head Office: Massachusetts, US; Chairman and CEO: Josef H. von Rickenbach) for business tie-up.

When international competition in the safety test industry is getting fierce with the ICH conference on drug development as an opportunity, Mitsubishi Chemical Safety Institute had been seeking the measures to establish a structure with international scope and quality at an early time. As a part of the measures, the company has concluded an agreement for business tie-up with Parexel to realize a strategic alliance with the leading CRO in the US.

Facing with lowered expenditures for drugs by patients due to the government's measures to suppress medical cost, direct participation in the Japanese market by foreign-capital manufacturers, severer competition in international level, increased cost for research and development, longer period for the development, and eased international regulations of ICH, pharmaceutical manufacturers of Japan try to develop new drugs aiming at launching in the international market before launching in Japan or at the same time.

The tie-up with Parexel, which have many experiences from clinical tests to applications for new drugs, together with our tie-up with MPI Research, a pre-clinical test organization in the US, in August last year will enable us to receive orders as a package covering from pre-clinical tests to new drug applications, marketing, and training. As a result, we are now able to cope with any stage of development by domestic pharmaceutical manufacturers, speed up the development, and improve the quality. By doing so, we believe we can provide development structure which makes domestic manufacturers entering into the international market easier and winning over the international competition. At the same time, we can also establish a business structure that can cope with the international competition and we are confident that we can establish a firm position in the industry worldwide.

back to top